Welcome to our dedicated page for Sotera Health Co SEC filings (Ticker: SHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sotera Health Company (SHC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sotera Health is a Nasdaq-listed provider of mission-critical sterilization solutions, lab testing and advisory services for the healthcare industry, operating through its Sterigenics, Nordion and Nelson Labs businesses.
Investors can review Form 8-K filings that report material events such as quarterly financial results, secondary offerings of common stock by selling stockholders, amendments to credit agreements and settlements of specific legal matters. For example, recent 8-Ks describe secondary offerings in which affiliates of Warburg Pincus LLC and GTCR LLC sold shares of SHC, with the company noting that it did not receive proceeds from those sales. Other 8-Ks outline amendments to a first lien credit agreement and the terms of repriced term loans maturing in 2031.
Filings also discuss legal and regulatory developments, including a binding term sheet to resolve a defined group of ethylene oxide claims related to a former Sterigenics facility, and broader risk factors associated with EO and Co-60, regulatory compliance, international operations and leverage. These disclosures help readers understand the legal, operational and financial context around Sotera Health’s sterilization and lab testing activities.
On Stock Titan, users can track new SHC filings as they appear on EDGAR and use AI-powered summaries to interpret complex documents. This includes understanding the implications of current reports on Form 8-K, as well as locating annual and quarterly reports when they are filed, to see segment information for Sterigenics, Nordion and Nelson Labs, capital structure details and updated risk factor discussions.
Sotera Health (SHC) reported stronger Q3 2025 results. Total revenue reached $311.3 million, up from $285.5 million a year ago, as Sterigenics and Nordion grew while Nelson Labs remained steady. Net income rose to $48.4 million from $17.0 million, with diluted EPS of $0.17 versus $0.06. For the first nine months, revenue was $860.2 million and net income was $43.1 million.
Cash generation and balance sheet improved. Year‑to‑date operating cash flow was $184.1 million, supporting capital spending and debt management. Long‑term debt declined to $2.129 billion from $2.208 billion. In September, the company repriced its term loan to Adjusted Term SOFR plus 2.50% and applied $75.0 million of cash to reduce borrowings; the average term‑loan rate fell to 7.22% in Q3 from 8.56% last year. Liquidity remained solid with $591.9 million available on the revolver.
Notable items. The company recorded $64.9 million year‑to‑date for Illinois EO litigation settlements and listed a $34.0 million related reserve in accrued liabilities at quarter‑end. Nordion’s Class 1B nuclear license was renewed for 25 years in September 2025. Shares outstanding were 284.1 million as of October 28, 2025.
Sotera Health (SHC)
The press release is attached as Exhibit 99.1 and incorporated by reference; the information is furnished and not deemed filed under the Exchange Act.
Sotera Health Company filed an 8-K reporting Amendment No. 6, dated September 17, 2025, to its First Lien Credit Agreement originally dated December 13, 2019. The amendment is among Sotera Health Company, Sotera Health Holdings, LLC, certain subsidiaries, JPMorgan Chase Bank, N.A. as First Lien Administrative Agent, and the 2025 Refinancing Term Lenders. The filing indicates the cover page interactive data is embedded within the Inline XBRL document. The 8-K is dated September 18, 2025 and was signed by Jonathan M. Lyons, Senior Vice President and Chief Financial Officer. The document notifies investors of a material amendment to the company’s secured credit arrangements but does not disclose the amendment’s specific terms or financial impact.
Sculptor Capital and affiliated entities report collective beneficial ownership of 14,750,000 common shares of Sotera Health Company, representing 5.19% of the outstanding class based on 284,046,606 shares. The stake is held across multiple related reporting persons (Sculptor Capital LP, Sculptor Capital II LP, Sculptor Capital Holding Corp, Sculptor Capital Holding II LLC, Sculptor Capital Management, Inc. and Sculptor Master Fund, Ltd.), each reporting shared voting and dispositive power of 14,750,000 shares and no sole voting or dispositive power. The filing states these shares are held in accounts managed by Sculptor and Sculptor-II and calculates percentages using the issuer’s 424B7 disclosed share count. The filing includes certifications that the position was not acquired to change or influence control of the issuer.
Sotera Health Co Schedule 13G/A discloses that a group of Warburg Pincus-related entities (the "WP Investors") together hold an aggregate of 103,038,253 shares of Sotera Health common stock, representing 36.3% of the outstanding class based on 284,046,606 shares outstanding per the issuer's July 29, 2025 prospectus. The filing describes a Stockholders Agreement between the WP Investors, GTCR investors and other holders that coordinates voting on certain director matters. The filing also notes 41,215,301 shares publicly reported as owned by GTCR in a Form 4 filed September 9, 2025 and states that WP Investors disclaim beneficial ownership of shares owned of record by GTCR except as set forth in the agreement.
GTCR-affiliated investors report joint beneficial ownership of 103,038,253 shares of Sotera Health Co., representing 36.3% of outstanding common stock. The group holds 41,215,301 shares of record while Warburg Pincus affiliates are reported to hold 61,822,952 shares; together the holders are party to a Stockholders Agreement that coordinates voting on certain director elections. The ownership percentage is calculated using 284,046,606 shares outstanding as disclosed in Sotera Health's prospectus supplement. Each GTCR Reporting Person disclaims beneficial ownership of shares held of record by the Warburg Pincus parties, and the GTCR Reporting Persons state they do not have dispositive power over the Warburg Pincus–held shares except as set forth in the Stockholders Agreement.
Warburg Pincus entities reported a secondary offering sale of Sotera Health Company (SHC) common stock. On 09/05/2025 the reporting group sold 12,000,000 shares of SHC at $15.111 per share in an underwritten public secondary offering, according to this Form 4.
After the transaction, the Warburg Pincus-related holders beneficially own 61,822,952 shares in the aggregate, comprised of 49,475,694 shares held by Bull Holdco L.P. and 12,347,258 shares held by Bull Co-Invest L.P. Multiple Warburg Pincus entities are listed as reporting persons and disclaim beneficial ownership except to the extent of their pecuniary interest. The filing is one of two reports relating to the same transactions.
Warburg Pincus entities disclosed a secondary sale of Sotera Health Company (SHC) shares. On 09/05/2025 certain Warburg Pincus Entities sold a total of 12,000,000 shares of SHC in an underwritten public secondary offering at a reported price of $15.111 per share. After the transaction the filing reports beneficial ownership of 61,822,952 shares held indirectly, consisting of 49,475,694 shares held by Bull Holdco L.P. and 12,347,258 shares held by Bull Co-Invest L.P. Multiple related Warburg Pincus entities are listed as reporting persons and disclaim beneficial ownership except to the extent of pecuniary interest. The filing notes this is 1 of 2 reports covering the same transactions.
Sotera Health Co. reporting persons affiliated with GTCR disclosed a sale of 8,000,000 shares of Sotera common stock on 09/05/2025 in an underwritten secondary offering at a price of $15.111 per share. After the sale, the GTCR XI Funds collectively beneficially own 41,215,301 shares, held across Fund XI/A, Fund XI/C and Co-Invest XI. The filing explains the ownership and control relationships among the GTCR entities and states that the reporting persons are directors-by-deputization solely for Section 16 purposes.
Sotera Health Company filed an 8-K reporting an underwriting agreement dated